Despite persistent racial and ethnic disparities in postoperative sepsis and septic shock risk, there is no evidence of inequity in regard to failure-to-rescue (FTR) rates for either condition. These ...

The shutdown of HHS web pages pertaining to HIV, LGBTQ+ health, and adolescent health raises questions about the future of infectious disease monitoring and research on these topics.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Distribution of prescribed opioid analgesics is lower in majority non-White versus majority White communities across all levels of socioeconomic deprivation.

Infant mortality rates decreased from 1999 to 2022, but infant mortality from sudden unexpected infant death increased significantly.

Exposure to cold in the Netherlands and to heat in Spain appears to be associated with more psychiatric symptoms among adolescents.

Vitamin D supplementation during TB treatment improves patient symptoms, but does not accelerate the clearance of TB bacteria.

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

COVID-19 was associated with more severe disease outcomes than influenza or RSV during the 2022 to 2023 season.

People still see COVID-19 as an ongoing public health threat, even though the pandemic officially ended in 2023.

For patients with HPV16-positive CIN3, vaccination with a replication-incompetent Semliki Forest virus vaccine encoding HPV16 E6 and E7 is safe and shows clinical effectiveness.